Jeffrey Chan (@jeffrey_d_chan) 's Twitter Profile
Jeffrey Chan

@jeffrey_d_chan

ai4science @lilasciences | previously @dyno_tx @googleai @apple @uberailabs | phd @berkeley_eecs + bs @mit.

ID: 1256063934332669955

calendar_today01-05-2020 03:32:54

21 Tweet

75 Followers

122 Following

Twist Bioscience (@twistbioscience) 's Twitter Profile Photo

Awesome infographic progress report of EBRC’s Research Roadmap for the Next-Generation Bioeconomy. An Assessment of Short-Term Milestones in EBRC’s 2019 Roadmap, Engineering Biology | EBRC Research Roadmap bit.ly/3LwjvyK

Awesome infographic progress report of <a href="/EngBioRC/">EBRC</a>’s Research Roadmap for the Next-Generation Bioeconomy.

An Assessment of Short-Term Milestones in EBRC’s 2019 Roadmap, Engineering Biology | EBRC Research Roadmap bit.ly/3LwjvyK
Niko McCarty 🧫 (@nikomccarty) 's Twitter Profile Photo

There have been an incredible number of gene-editing advances (including in delivery) over the last three days. Here are 7 of them...🧵

Brian Naughton (@btnaughton) 's Twitter Profile Photo

interesting conclusion from the EigenFold paper, which generates a distribution of structures from sequence arxiv.org/pdf/2304.02198…

interesting conclusion from the EigenFold paper, which generates a distribution of structures from sequence arxiv.org/pdf/2304.02198…
Stephen Malina (@an1lam) 's Twitter Profile Photo

I will be at SynBioBeta and we'll be hosting a panel! As Sam mentioned, we'll discuss how steering is under-attended in our field and why we think it's so important. This may include some hot takes, but you'll have to come to find out what they are. Please reach out if you're

Stephen Malina (@an1lam) 's Twitter Profile Photo

I just finished a post on the R&D timeline of Humira, the quintessential blockbuster drug (>$200B revenue so far). Big takeaway: time for fundamental science + tech dev timelines >> human trials in this case, which was a big update for me.

I just finished a post on the R&amp;D timeline of Humira, the quintessential blockbuster drug (&gt;$200B revenue so far).

Big takeaway: time for fundamental science + tech dev timelines &gt;&gt; human trials in this case, which was a big update for me.
Andrew Beam (@andrewlbeam) 's Twitter Profile Photo

Can science create the next scaling paradigm for AI? We think so, and we'll be using our recent Series A raise to build a new kind of scientific reasoning model at scale. If you're interested in how we think all of science is subject to the bitter lesson, read on in the 🧵👇

Yun S. Song (@yun_s_song) 's Twitter Profile Photo

We are excited to share GPN-Star, a cost-effective, biologically grounded genomic language modeling framework that achieves state-of-the-art performance across a wide range of variant effect prediction tasks relevant to human genetics. biorxiv.org/content/10.110… (1/n)

We are excited to share GPN-Star, a cost-effective, biologically grounded genomic language modeling framework that achieves state-of-the-art performance across a wide range of variant effect prediction tasks relevant to human genetics.
biorxiv.org/content/10.110…
(1/n)
Corin Wagen (@corinwagen) 's Twitter Profile Photo

I attended the 2025 Progress Conference and had a lot of interesting conversations about agentic AI for science, which prompted me to write down some thoughts I've been developing on this topic. Here's seven thoughts on the future of "AI scientists": corinwagen.github.io/public/blog/20…

Adam Marblestone (@adammarblestone) 's Twitter Profile Photo

Jacob Rintamaki I engaged with it a tiny bit back in the day x.com/AdamMarbleston… Here is a bit more engagement: Tamay and Ege recently claimed that most R&D progress isn’t the result of genius scientific reasoning – or more generally of smart researchers doing what looks like

Richard Fuisz (@richardfuisz) 's Twitter Profile Photo

Reposting my comment from a groupchat; thought the conversation was interesting so sharing here: It used to be that you could get patents for “antibody that hits X”. These days you can only get a patent on “antibody with sequence Y that hits target X”. This is much easier to

Richard Fuisz (@richardfuisz) 's Twitter Profile Photo

Some exciting news to share — we've made the world's first magnetically controlled antibody! What is a magnetically controlled antibody? It's an antibody drug that you can turn on and off, wherever you want in the body. (1/9) x.com/ashleevance/st…

Jeffrey Chan (@jeffrey_d_chan) 's Twitter Profile Photo

Congrats to the OF3 team! Open-source models on top of preexisting open-weight models will be a step change for the broader AI bio community

Jeffrey Chan (@jeffrey_d_chan) 's Twitter Profile Photo

My bet is that scientific reasoning won’t be achieved purely via the o1 era RLVR paradigm but will still have some RL characteristics.